Cargando…
The effect of empagliflozin on the total burden of cardiovascular and hospitalization events in the Asian and non‐Asian populations of the EMPA‐REG OUTCOME trial of patients with type 2 diabetes and cardiovascular disease
AIMS: The sodium‐glucose co‐transporter 2 inhibitor empagliflozin reduced the total burden of cardiovascular, mortality, and all‐cause hospitalization events, including first and recurrent events, in EMPA‐REG OUTCOME participants with type 2 diabetes (T2D) and established atherosclerotic cardiovascu...
Autores principales: | Kaku, Kohei, Wanner, Christoph, Anker, Stefan D., Pocock, Stuart, Yasui, Atsutaka, Mattheus, Michaela, Lund, Søren S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Blackwell Publishing Ltd
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9305124/ https://www.ncbi.nlm.nih.gov/pubmed/34908223 http://dx.doi.org/10.1111/dom.14626 |
Ejemplares similares
-
Relationship between hypoglycaemia, cardiovascular outcomes, and empagliflozin treatment in the EMPA-REG OUTCOME(®) trial
por: Fitchett, David, et al.
Publicado: (2020) -
Cardiovascular Benefit of Empagliflozin Across the Spectrum of Cardiovascular Risk Factor Control in the EMPA-REG OUTCOME Trial
por: Inzucchi, Silvio E, et al.
Publicado: (2020) -
Time to cardiovascular benefits of empagliflozin: a post hoc observation from the EMPA‐REG OUTCOME trial
por: Verma, Subodh, et al.
Publicado: (2021) -
Empagliflozin and kidney outcomes in Asian patients with type 2 diabetes and established cardiovascular disease: Results from the EMPA‐REG OUTCOME(®) trial
por: Kadowaki, Takashi, et al.
Publicado: (2019) -
Empagliflozin and uric acid metabolism in diabetes: A post hoc analysis of the EMPA‐REG OUTCOME trial
por: Ferreira, João Pedro, et al.
Publicado: (2021)